表紙
市場調査レポート

世界の遺伝子組換えタンパク質医薬品市場

Global Markets for Bioengineered Protein Drugs

発行 BCC Research 商品コード 311228
出版日 ページ情報 英文 189 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
世界の遺伝子組換えタンパク質医薬品市場 Global Markets for Bioengineered Protein Drugs
出版日: 2014年08月27日 ページ情報: 英文 189 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2013年、世界の遺伝子組換えタンパク質医薬品の市場は1,519億ドルの規模を記録し、2014年には約1,570億ドルの規模に達すると予測されています。さらに2014年から2019年にかけては7.2%のCAGRで推移し、2019年には約2,227億ドルに成長すると予測されています。

当レポートでは、世界の遺伝子組換えタンパク質医薬品の市場について調査し、遺伝子組換えタンパク質医薬品の概要、発展の経緯、製造および投与技術、分類、新規承認関連の動向、新たな開発の動向、薬剤の分類・適応症・地域別の市場概要および市場収益の推移と予測、産業構造と主要事業者の市場シェア、特許情報、主要事業者のプロファイルなどを詳細に渡ってまとめています。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • タンパク質の合成
  • 遺伝子組換えタンパク質医薬品の歴史
  • 遺伝子組換えタンパク質医薬品

第4章 法規制的側面

  • モノクローナル抗体
  • サイトカイン
  • ワクチン
  • ペプチドホルモン
  • 治療用酵素
  • 血液製剤
  • リコール
  • 新薬の申請/生物学的製剤承認申請
  • 安全性に関する警笛

第5章 新たな開発

  • ワクチン
  • ペプチドホルモン
  • 治療用酵素
  • 血液製剤
  • ペプチド抗体
  • サイトカイン
  • モノクローナル抗体
  • M&A
  • 新技術
    • 生物製剤のイノベーション
    • 融合タンパク質
    • ナノメディシン
    • 改変足場タンパク質
    • プログラム化バイオ製造

第6章 遺伝子組換えタンパク質医薬品の市場分析

  • タイプ別市場
    • 世界の遺伝子組換えタンパク質医薬品市場
    • ペプチドホルモン
    • ワクチン
    • 治療用酵素
    • モノクローナル抗体
    • サイトカイン
    • 血液製剤 AND ペプチド抗体
    • 市場シェア
  • 地域別市場
    • 市場概要
    • 市場収益
    • 市場シェア

第7章 遺伝子組換えタンパク質医薬品の市場:疾患別

  • 疾患別市場
    • 世界の遺伝子組換えタンパク質医薬品の市場:疾患別
    • 糖尿病
    • 血液障害・皮膚疾患
    • 成長ホルモン障害・酵素障害・受胎障害
    • その他

第8章 遺伝子組換えタンパク質医薬品:産業構造

  • 産業構造
    • モノクローナル抗体
    • ペプチドホルモン
    • サイトカイン
    • 治療用酵素
    • ワクチン
    • 血液製剤
    • ペプチド抗体

第9章 特許分析

第10章 現在の状況

  • 遺伝子組換えタンパク質医薬品への影響因子

第11章 企業プロファイル

第12章 付録

図表

目次
Product Code: BIO009F

The global market for bioengineered protein drugs was valued at $151.9 billion in 2013 and will reach about $157.0 billion in 2014. The market is further expected to grow to about $222.7 billion in 2019, a compound annual growth rate (CAGR) of 7.2% from 2014 through 2019.

This report provides:

  • An overview of the global market for bioengineered protein drugs.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Coverage of proteins that are used for therapeutic purposes, including an analysis of protein-based drugs in clinical trials.
  • A look at current technologies underlying the market as well as the effects new technologies will have on the market.
  • An analysis of the patent landscape in this field and the companies with the greatest breadth in their IP portfolios.
  • Profiles of the major companies involved in the production and modification of protein drugs.

image1

REPORT SCOPE

SCOPE OF THE STUDY

The scope of this study involves the bioengineered protein therapeutics used in the pharmaceutical and the biopharmaceutical markets. BCC Research analyzes each market and its applications, regulatory environment, technologies involved, market projections and market shares. The technological issues include all the latest trends, pipeline products and developments. The emerging markets cover countries such as India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

The bioengineered protein drugs that are covered in this report are monoclonal antibodies, cytokines, peptide antibiotics, vaccines, enzymes, peptide hormones and blood factors. These products are bioengineered and are produced by recombinant DNA technology. The only blood products considered in this report are recombinant blood products which are derived through the recombinant DNA technology process.

ANALYST'S CREDENTIALS

A team of professionals in the biotechnology industry carried out this study. The project manager is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S.

Some of her other reports with BCC Research are:

  • Global Markets for Reagents for Chromatography.
  • Global Markets for Spectroscopy Equipment.
  • Global Markets and Technologies for Advanced Drug Delivery Systems.
  • Orthopedic Drugs, Implants and Devices.
  • Global Markets for Medical Imaging Reagents and Analysis Equipment.
  • Pharmaceutical Regulatory Industry.
  • Global Markets for Media, Sera and Reagents in Biotechnology.
  • Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging.
  • Global Markets for Chiral Technology.
  • Autacoids and Related Drugs: Technologies and Global Markets.
  • Contraceptives: Technologies and Global Markets.
  • Liver Disease Treatments: The Global Market.
  • Hormone Replacement Therapies and Other Hormone Therapies: Global Markets.
  • Cardiovascular Medicine: Diagnostics, Drugs and Devices.
  • Cancer Therapies: Technologies and Global Markets.
  • Medical Imaging Reagents and Analysis Equipment.

The lead analysts for this project were Honey Dave and Lakshmi Prasanna. Both analysts hold masters in biotechnology. They have written many research publications and their interests include proteomics, genomics, pharmacology and gene sequencing.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • BIOSYNTHESIS OF PROTEINS
    • TRANSCRIPTION
    • TRANSLATION
    • POST-TRANSCRIPTIONAL MODIFICATIONS
    • SUMMARY FIGURE
  • HISTORY OF BIOENGINEERED PROTEIN DRUGS
  • TABLE 1 EVOLUTION OF BIOENGINEERED PROTEINS DRUGS
  • BIOENGINEERED PROTEIN DRUGS
  • TABLE 2 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
    • ADVANTAGES OF BIOENGINEERED PROTEIN DRUGS
    • MANUFACTURING TECHNOLOGY
      • Fractionation or Cohn Process
      • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
      • Microbial Cell Fermentation and Bioreactors
      • TABLE 4 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
      • Genetic Engineering
      • Genetically Modified Organisms
      • Pharming
      • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICRO-ORGANISMS
      • Mammalian Cell Culture
      • TABLE 6 PROTEIN DRUGS MADE BY CELL CULTURE
      • Cell-Free Protein Synthesis Systems
    • ADMINISTRATION TECHNOLOGIES OF BIOENGINEERED PROTEIN DRUGS
      • Traditional Methods of Drug Delivery
        • Oral
        • Topical
        • Transmucosal
        • Inhalation
        • Parenteral
        • TABLE 7 ROUTES OF DRUG DELIVERY
      • Limitations Encountered by Traditional Drug Delivery
      • Current Research and Novel Approaches
        • Targeted Drug Delivery Carriers
        • Micelles
        • Liposomes
        • Microspheres
        • Nanoparticles
        • Microemulsions
        • Hydrogels
        • Thin-film Drug Delivery
        • Prodrug
    • MOLECULAR CLASSIFICATION OF PROTEIN DRUGS
      • Monoclonal Antibodies
      • Cytokines
        • Interferons
        • Interleukins
        • Colony Stimulating Factors
      • Peptide Hormones
        • Follicle Stimulating Hormones and Luteinizing Hormones
        • Growth Hormones
        • Erythropoietin
        • Insulin
      • Vaccines
        • Live Attenuated Vaccines
        • Inactivated/Killed Vaccines
        • Toxoid
        • Subunit/Conjugate
      • Therapeutic Enzymes
        • Digestive Enzymes
        • Metabolic Enzymes
        • Other Enzymes
      • Peptide Antibiotics
      • Blood Products
        • Alpha 1-Protease Inhibitor
        • Antihemophilic Factor
        • Antithrombin
        • C1 Esterase Inhibitor
        • Coagulation Factors
        • Immune Globulins
        • Protein C
        • Thrombin

CHAPTER 4 REGULATORY ASPECTS

  • MONOCLONAL ANTIBODIES
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2009-MAY 2014
  • CYTOKINES
  • TABLE 9 NEW APPROVALS OF CYTOKINES, 2009-MAY 2014
  • VACCINES
  • TABLE 10 NEW APPROVALS IN VACCINES, 2009-MAY 2014
  • PEPTIDE HORMONES
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES, 2009-MAY 2014
  • THERAPEUTIC ENZYMES
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2009-MAY 2014
  • BLOOD PRODUCTS
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS, 2009-MAY 2014
  • RECALLS
  • TABLE 14 RECALLS, FROM 2009 TO MAY 2014
  • NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS
  • TABLE 15 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS, FROM 2009 TO MAY 2014
  • SAFETY ALERTS
  • TABLE 16 SAFETY ALERTS, FROM 2009 TO MAY 2014

CHAPTER 5 NEW DEVELOPMENTS

  • VACCINES
  • TABLE 17 PIPELINE PRODUCTS IN VACCINES
  • PEPTIDE HORMONES
  • TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES
  • THERAPUETIC ENZYMES
  • TABLE 19 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES
  • BLOOD PRODUCTS
  • TABLE 20 PIPELINE PRODUCTS IN BLOOD PRODUCTS
  • PEPTIDE ANTIBIOTICS
  • TABLE 21 PIPELINE PRODUCTS OF PEPTIDE ANTIBIOTICS
  • CYTOKINES 62
  • TABLE 22 PIPELINE PRODUCTS OF CYTOKINES
  • MONOCLONAL ANTIBODIES
  • TABLE 23 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • MERGERS AND ACQUISITIONS
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES, 2009 TO FEBRUARY 2014
  • NEW TECHNOLOGIES
    • INNOVATIONS IN BIOLOGIC DRUGS
    • FUSION PROTEIN
    • NANOMEDICINE
    • ENGINEERED PROTEIN SCAFFOLDS
    • PROGRAMMED BIOMANUFACTURING

CHAPTER 6 MARKET ANALYSIS OF BIOENGINEERED PROTEIN DRUGS

  • MARKET BY TYPE
    • GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET
    • TABLE 25 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 1 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2012-2019 ($ MILLIONS)
    • PEPTIDE HORMONES
      • Market Overview
      • Market Revenue
      • TABLE 26 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 2 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2012-2019 ($ MILLIONS)
    • VACCINES
      • Market Overview
      • Market Revenue
      • TABLE 27 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 3 GLOBAL MARKET FOR VACCINES BY REGION, 2012-2019 ($ MILLIONS)
    • THERAPEUTIC ENZYMES
      • Market Overview
      • Market Revenue
      • TABLE 28 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2012-2019 ($ MILLIONS)
    • MONOCLONAL ANTIBODIES
      • Market Overview
      • Market Revenue
      • TABLE 29 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 5 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
    • CYTOKINES
      • Market Overview
      • Market Revenue
      • TABLE 30 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 6 GLOBAL MARKET FOR CYTOKINES BY REGION, 2012-2019 ($ MILLIONS)
    • BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS
      • Market Overview
      • Market Revenue
      • TABLE 31 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 7 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
      • TABLE 32 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)
      • FIGURE 8 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)
  • MARKET BY REGION
    • MARKET OVERVIEW
    • MARKET REVENUE
    • TABLE 33 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 9 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 ($ MILLIONS)
    • MARKET SHARE
    • TABLE 34 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)
    • FIGURE 10 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)

CHAPTER 7 MARKET BY DISEASES OF BIOENGINEERED PROTEIN DRUGS

  • MARKET BY DISEASES
    • GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET BY DISEASES
    • TABLE 35 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2019 ($ MILLIONS)
    • FIGURE 11 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2012-2019 ($ MILLIONS)
    • DIABETES
      • Type 1 Diabetes
      • Type 2 Diabetes
      • Gestational Diabetes
      • Market Overview
      • Market Revenue
      • TABLE 36 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 12 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2012-2019 ($ MILLIONS)
      • Market Share
      • TABLE 37 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)
      • FIGURE 13 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)
    • CANCER
      • TABLE 38 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN
      • TABLE 39 CATEGORIES OF CANCER
      • Market Overview
      • Market Revenue
      • TABLE 40 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 14 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2012-2019 ($ MILLIONS)
      • Market Share
      • TABLE 41 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)
      • FIGURE 15 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)
    • BLOOD DISORDERS AND SKIN DISEASES
      • Blood Disorders
        • Bleeding Disorders
        • Anemia
        • Leukemia
        • Multiple Myeloma
      • Skin Diseases
        • Skin and Skin structure Infections (SSSI)
          • Complicated Skin and Skin Structure Infection (cSSSI)
          • Uncomplicated Skin and Skin Structure Infection (uSSSI)
            • Clostridium difficile (C.difficile)
      • Market Overview
      • Market Revenue
      • TABLE 42 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2012-2019 ($ MILLIONS)
      • Market Share
      • TABLE 43 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)
      • FIGURE 17 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)
    • GROWTH HORMONE DISORDER, ENZYME DISORDER AND FERTILITY DISORDER
      • Market Overview
      • Market Revenue
      • TABLE 44 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2012-2019 ($ MILLIONS)
      • Market Share
      • TABLE 45 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)
      • FIGURE 19 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)
    • OTHERS
      • Rheumatoid Arthritis
      • Multiple Sclerosis
      • Crohn's Disease
      • Hepatitis
      • Influenza
      • Pneumonia
      • Cystic Fibrosis
      • Meningitis
      • Asthma
      • Market Overview
      • Market Revenue
      • TABLE 46 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, THROUGH 2019 ($ MILLIONS)
      • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2012-2019 ($ MILLIONS)
      • Market Share
      • TABLE 47 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)
      • FIGURE 21 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)

CHAPTER 8 INDUSTRY STRUCTURE OF BIOENGINEERED PROTEIN DRUGS

  • INDUSTRY STRUCTURE OF BIOENGINEERED PROTEIN DRUGS, 2013
    • MONOCLONAL ANTIBODIES
    • TABLE 48 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013
      • Market Share
      • TABLE 49 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)
      • FIGURE 22 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)
    • PEPTIDE HORMONES
      • TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013
      • Market Share
      • TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)
      • FIGURE 23 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)
    • CYTOKINES
      • TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2013
      • Market Share
      • TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)
      • FIGURE 24 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)
    • THERAPEUTIC ENZYMES
      • TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013
      • Market Share
      • TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)
      • FIGURE 25 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)
    • VACCINES
      • TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2013
      • Market Share
      • TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)
      • FIGURE 26 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)
    • BLOOD PRODUCTS
      • TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013
      • Market Share
      • TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)
      • FIGURE 27 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)
    • PEPTIDE ANTIBIOTICS
      • TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013
      • Market Share
      • TABLE 61 MARKET SHARE OF MANUFACTURERS/ SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)
      • FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)

CHAPTER 9 PATENT ANALYSIS

  • PATENTS BY YEAR
  • TABLE 62 NUMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • FIGURE 29 UMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (%)
  • PATENTS BY TYPE/ CATEGORY
  • TABLE 63 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • FIGURE 30 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • PATENTS BY COMPANY
  • TABLE 64 NUMBER OF PATENTS, BY COMPANY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • PATENTS BY COUNTRY
  • TABLE 65 NUMBER OF PATENTS, BY COUNTRY, JANUARY 2009 -FEBRUARY 2014 (NUMBER OF PATENTS)
  • TABLE 66 PATENT SHARES, BY COUNTRY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS/%)
  • PATENTS BY ASSIGNEE
  • TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)

CHAPTER 10 THE CURRENT SITUATION

  • FACTORS AFFECTING BIOENGINEERED PROTEIN DRUGS
    • INCREASING PREVALENCE OF CHRONIC DISEASES
    • GROWING AGING POPULATION
    • LIFESTYLE CHANGES
    • NEW PRODUCT LAUNCHES
    • ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES
    • PRICE CONTROLS
    • REGULATORY PRESSURES
    • ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS
    • LICENSING AGREEMENTS
    • MERGERS AND ACQUISITIONS

CHAPTER 11 COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ACTAVIS INC. (FORMERLY WATSON LABS)
  • ALEXION PHARMACEUTICALS
  • ALLERGAN INC.
  • AMGEN
  • BAXTER HEALTHCARE
  • BAYER HEALTHCARE PHARMACEUTICALS
  • BIOGEN IDEC INC.
  • BIOMARIN PHARMACEUTICAL INC.
  • BRISTOL-MYERS SQUIBB CO.
  • CSL LIMITED
  • ELI LILLY AND CO.
  • FRESENIUS KABI USA
  • GLAXOSMITHKLINE
  • HOFFMAN-LA-ROCHE
  • HOSPIRA
  • JOHNSON & JOHNSON
  • LUNDBECK LLC
  • MEDIMMUNE LLC
  • MERCK & CO. INC.
  • MERCK KGAA
  • MYLAN INC.
  • NOVARTIS
  • NOVO NORDISK INC.
  • PFIZER INC.
  • SANDOZ
  • SANOFI
  • SEATTLE GENETICS INC.
  • TAKEDA PHARMACEUTICAL U.S.A. INC.
  • UCB COMPANY
  • VIROPHARMA INC.
  • VERTEX PHARMACEUTICALS
  • WOCKHARDT LTD.
  • X-GEN PHARMACEUTICALS INC.
  • ZYMOGENETICS INC.

CHAPTER 12 APPENDIX-ABBREVIATIONS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 EVOLUTION OF BIOENGINEERED PROTEINS DRUGS
  • TABLE 2 BIOENGINEERED PROTEIN DRUGS VS. CHEMICALLY SYNTHESIZED DRUGS
  • TABLE 3 PROTEIN DRUGS MADE BY FRACTIONATION
  • TABLE 4 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION
  • TABLE 5 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICRO-ORGANISMS
  • TABLE 6 PROTEIN DRUGS MADE BY CELL CULTURE
  • TABLE 7 ROUTES OF DRUG DELIVERY
  • TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2009-MAY 2014
  • TABLE 9 NEW APPROVALS OF CYTOKINES, 2009-MAY 2014
  • TABLE 10 NEW APPROVALS IN VACCINES, 2009-MAY 2014
  • TABLE 11 NEW APPROVALS IN PEPTIDE HORMONES, 2009-MAY 2014
  • TABLE 12 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2009-MAY 2014
  • TABLE 13 NEW APPROVALS IN BLOOD PRODUCTS, 2009-MAY 2014
  • TABLE 14 RECALLS, FROM 2009 TO MAY 2014
  • TABLE 15 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS, FROM 2009 TO MAY 2014
  • TABLE 16 SAFETY ALERTS, FROM 2009 TO MAY 2014
  • TABLE 17 PIPELINE PRODUCTS IN VACCINES
  • TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES
  • TABLE 19 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES
  • TABLE 20 PIPELINE PRODUCTS IN BLOOD PRODUCTS
  • TABLE 21 PIPELINE PRODUCTS OF PEPTIDE ANTIBIOTICS
  • TABLE 22 PIPELINE PRODUCTS OF CYTOKINES
  • TABLE 23 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES
  • TABLE 24 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES, 2009 TO FEBRUARY 2014
  • TABLE 25 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, THROUGH 2019 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)
  • TABLE 33 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 34 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)
  • TABLE 35 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, THROUGH 2019 ($ MILLIONS)
  • TABLE 36 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 37 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)
  • TABLE 38 VARIOUS CANCER TYPES DEPENDING ON THE TISSUE OF ORIGIN 116 TABLE 39 CATEGORIES OF CANCER
  • TABLE 40 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 41 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)
  • TABLE 42 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 43 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)
  • TABLE 44 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 45 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)
  • TABLE 46 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, THROUGH 2019 ($ MILLIONS)
  • TABLE 47 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)
  • TABLE 48 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013
  • TABLE 49 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)
  • TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013
  • TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)
  • TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2013
  • TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)
  • TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013
  • TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)
  • TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2013
  • TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)
  • TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013
  • TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)
  • TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013
  • TABLE 61 MARKET SHARE OF MANUFACTURERS/ SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)
  • TABLE 62 NUMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • TABLE 63 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • TABLE 64 NUMBER OF PATENTS, BY COMPANY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • TABLE 65 NUMBER OF PATENTS, BY COUNTRY, JANUARY 2009 -FEBRUARY 2014 (NUMBER OF PATENTS)
  • TABLE 66 PATENT SHARES, BY COUNTRY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS/%)
  • TABLE 67 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 ($ MILLIONS)
  • SUMMARY FIGURE
  • FIGURE 1 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY TYPE, 2012-2019 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR VACCINES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET FOR CYTOKINES BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 7 GLOBAL MARKET FOR BLOOD PRODUCTS AND PEPTIDE ANTIBIOTICS BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 8 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY TYPE, IN 2013 (%)
  • FIGURE 9 GLOBAL REVENUE OF BIOENGINEERED PROTEIN DRUGS BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 10 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY REGION, IN 2013 (%)
  • FIGURE 11 GLOBAL SALES FOR BIOENGINEERED PROTEIN DRUGS, BY DISEASE, 2012-2019 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 13 MARKET SHARE OF BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN DIABETES, BY REGION, 2013 (%)
  • FIGURE 14 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 15 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN CANCER, BY REGION, 2013 (%)
  • FIGURE 16 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 17 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN BLOOD DISORDERS AND SKIN DISEASES, BY REGION, 2013 (%)
  • FIGURE 18 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 19 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN GROWTH HORMONE, ENZYME AND FERTILITY DISORDERS, BY REGION, 2013 (%)
  • FIGURE 20 GLOBAL MARKET FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2012-2019 ($ MILLIONS)
  • FIGURE 21 MARKET SHARE FOR BIOENGINEERED PROTEIN DRUGS BY APPLICATION IN OTHER DISEASES, BY REGION, 2013 (%)
  • FIGURE 22 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2013 (%)
  • FIGURE 23 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2013 (%)
  • FIGURE 24 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF CYTOKINE, 2013 (%)
  • FIGURE 25 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2013 (%)
  • FIGURE 26 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF VACCINES, 2013 (%)
  • FIGURE 27 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT BLOOD PRODUCTS, 2013 (%)
  • FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2013 (%)
  • FIGURE 29 UMBER OF PATENTS, BY YEAR, JANUARY 2009-FEBRUARY 2014 (%)
  • FIGURE 30 NUMBER OF PATENTS, BY CATEGORY, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
  • FIGURE 31 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-FEBRUARY 2014 (NUMBER OF PATENTS)
Back to Top